Welcome to Markets Desk, here's what's moving right now.
Australian equities are holding modest gains through the midday session, with the S&P ASX two hundred clinging to positive territory after drawing support from overnight strength on Wall Street. The gains are modest and the session has softened from its opening highs, but the directional read remains constructive heading into the close.
Shifting to medtech, GRAIL shares have climbed back above one hundred dollars ahead of a critical FDA advisory panel review Wednesday for its Galleri multi-cancer early detection test. The panel outcome carries significant commercial weight — a favorable read could validate the company's path to broader clinical adoption and reshape how the market prices the stock longer term.
And in corporate news, Nyxoah has announced its chief financial officer John Landry will step down effective October second, two thousand twenty six, with Moreau named interim CFO. Notably, the company reaffirmed its full-year two thousand twenty six guidance alongside the announcement, a deliberate signal meant to reassure investors that the leadership transition carries no revision risk to the financial outlook.
That's the tape. Markets Desk, signing off the floor.
